DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Recruiting
Prof. W. Janni
Phase 2
2014-01-01
Several studies have indicated that determining prevalence and number of circulating tumor
cells (CTCs) at various time points during treatment may be an effective tool for assessing
treatment efficacy in metastatic breast cancer (MBC). However, even if the prognostic value
of CTCs in MBC is well understood, the role of both CTC prevalence and CTC phenotype in
predicting treatment response needs further investigation. DETECT IV is a prospective,
multicenter, open-label, phase II study in patients with HER2-negative metastatic breast
cancer and persisting HER2-negative circulating tumor cells (CTCs). Additional research on
CTC dynamics and characteristics will provide a better understanding of the prognostic and
predictive value of CTCs and is one step into a more personalized therapy for MBC.
Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin®
(trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2
positive and hormone-receptor positive metastatic breast cancer.
Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin®
(trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2
positive and hormone-receptor positive metastatic breast cancer.
Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin®
(trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2
positive and hormone-receptor positive metastatic breast cancer.
Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin®
(trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2
positive and hormone-receptor positive metastatic breast cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
